Leerink Partners analyst Mani Foroohar has maintained their bullish stance on IONS stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mani Foroohar’s rating is based on several positive developments at Ionis Pharmaceuticals. The company has reported strong second-quarter results for 2025, with a significant increase in their full-year guidance. This is largely due to the successful launch of Tryngolza for familial chylomicronemia syndrome (FCS), which has exceeded sales expectations. Additionally, the upcoming Phase 3 data for olezarsen in severe hypertriglyceridemia (SHTG) presents a promising opportunity, particularly in reducing acute pancreatitis incidents.
Furthermore, Ionis is poised for another commercial launch with donidalorsen for hereditary angioedema (HAE) and is advancing its pipeline with new trials, such as the REVEAL trial for Angelman syndrome. The company’s partnerships are also progressing, with Biogen advancing salanersen into pivotal studies for spinal muscular atrophy and AstraZeneca initiating a study for opemalirsen in kidney disease, which has already triggered a milestone payment. These factors collectively contribute to a positive outlook for Ionis Pharmaceuticals, justifying the Buy rating.
In another report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $78.00 price target.
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IONS in relation to earlier this year.